Exercise Intolerance in Heart Failure
Johns Hopkins University · with National Heart, Lung, and Blood Institute (NHLBI) · NCT03775577
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 21+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 130
- US sites recruiting
- 1
- Study start
- April 1, 2017
- Record last updated
- March 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.
Conditions: Heart Failure With Normal Ejection Fraction
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patients of either gender who are greater than 21 years of age (no upper age limit),
- Permission of patient's clinical attending physician,
- Previous clinical diagnosis of HF with current New York Heart Association (NYHA) Class II-III symptoms for at least 1 month,
- Left ventricular ejection fraction (EF) >50% by echocardiography, MRI, CT or x-ray or nuclear ventriculography within prior 12 months,
- Stable medical therapy for at least 30 days (no addition or removal or major (>100%) dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists, beta-blockers, or calcium channel blockers for hypertension).
Exclusion Criteria
- Unable to understand the risks, benefits, and alternatives of participation and give meaningful consent,
- Contraindications to MRI such as implanted metallic objects (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,
- Significant valvular abnormalities,
- Pregnant women (women of childbearing potential will undergo blood or urine pregnancy testing),
- History of clinical CAD or significant epicardial coronary disease (>50% stenosis) in major coronary artery by x-ray or CT angiography unless (a) the patient underwent prior successful revascularization with percutaneous coronary angioplasty within the prior three years and (b) there are no residual lesions of >50% on the most recent coronary angiographic study.
- History of infiltrative cardiomyopathy or constrictive pericarditis,
- Cor pulmonale,
- Significant pulmonary disease,
- Estimated glomerular filtration rate (eGFR) \<20ml/min,
- Any condition other than HF which could limit the ability to perform a 6MW or cardiopulmonary exercise test (CPET) test (e.g., critical peripheral vascular disease, significant orthopedic or neurological conditions),
- Any diseases other than HF which are likely to significantly alter the patient's global perception of status or quality of life over a period of 6 months.
- Significant peripheral vascular disease
Recruiting US locations
Johns Hopkins Hospital
Baltimore, MD 21287
Site contact: Tricia Steinberg, MSN · 443-287-3469 · asteinb3@jhmi.edu
Study contacts (from the official record)
- Matthew Kauffman · 443-287-3475 · mkauffm7@jhmi.edu
- Tricia Steinberg, RN, MSN · 443-287-3469 · asteinb3@jhmi.edu
Similar studies in Maryland
All heart & blood pressure studies in Maryland →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Study of Intravenous ZMA001 in Healthy Subjects
National Heart, Lung, and Blood Institute (NHLBI)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 18–60
- RecruitingHealthy volunteersPhase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
National Heart, Lung, and Blood Institute (NHLBI)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 18–99
- RecruitingHealthy volunteers
BoxX-NoAF Clinical Trial
AtriCure, Inc.
- Location
- Baltimore, MD + 30 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Pfizer
- Location
- Baltimore, MD + 27 other US sites
- Eligibility basics
- Ages 18–79